High cure rates for HCV genotype 6 in advanced liver fibrosis with 12 weeks sofosbuvir and daclatasvir: The Vietnam SEARCH Study
Background Genotype 6 is the most genetically diverse lineage of hepatitis C virus (HCV), and predominates in Vietnam. It can be treated with sofosbuvir with daclatasvir (SOF/DCV), the lowest costing treatment combination globally. In regional guidelines, longer treatment durations of SOF/DCV (24 we...
Автори: | Flower, B, McCabe, L, Ngoc, CL, Hung, LM, Phuong, LT, Trong, TD, Thi, TV, Kim, HVT, Tat, TN, Hong, DPT, Chau, ANT, Thi, TD, Tuyet, NTT, Tarning, J, Kingsley, C, Kestelyn, E, Pett, SL, Thwaites, G, Chau, NVV, Smith, D, Barnes, E, Ansair, A, Turner, H, Rahman, M, Walker, AS, Day, J, Cooke, GS |
---|---|
Формат: | Journal article |
Мова: | English |
Опубліковано: |
Oxford University Press
2021
|
Схожі ресурси
Схожі ресурси
-
Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study
за авторством: Barnaby Flower, та інші
Опубліковано: (2023-01-01) -
Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study
за авторством: Flower, B, та інші
Опубліковано: (2023) -
Combination of Sofosbuvir-Ledipasvir and Sofosbuvir- Daclatasvir for Treatment HCV Patients in Indonesia
за авторством: Andri Sanityoso Sulaiman, та інші
Опубліковано: (2023-12-01) -
TREATMENT OF HCV INFECTION BY A COMBINATION OF SOFOSBUVIR AND DACLATASVIR
за авторством: Y. O. SHULPEKOVA, та інші
Опубліковано: (2017-05-01) -
Daclatasvir/Sofosbuvir versus Ledipasvir/Sofosbuvir in Patients with Hepatitis C Virus Infection Genotypes 1 and 3
за авторством: Narjes Shokatpour, та інші
Опубліковано: (2020-06-01)